There are 2789 resources available
982P - A phase II study of SHR-1701 plus famitinib for patients with previously treated advanced pancreatic cancer or biliary tract cancer
Presenter: jing xie
Session: ePoster Display
983P - Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein α (SIRPα) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor
Presenter: Nuria Kotecki
Session: ePoster Display
1154P - Circulating tumor DNA analysis integrating tumor clonality detects minimal residual disease in resectable non-small cell lung cancer
Presenter: Rong Yin
Session: ePoster Display
1155P - Univariable and multivariable two-sample Mendelian randomization investigating the effects of leisure sedentary behavior on the risk of lung cancer
Presenter: Haoxin Peng
Session: ePoster Display
1156P - Exosomal lncRNA HOTTIP assessment for non-small cell lung cancer surveillance after curative-intent surgery
Presenter: Han Bing
Session: ePoster Display
1157P - Diagnostic therapeutic pathway (DTP) of early stage non-small cell lung cancer (eNSCLC): A real-world focus on EGFR status detection in resected patients (pts)
Presenter: Giulia Pasello
Session: ePoster Display
1158P - Real-world adjuvant treatment patterns and survival outcomes among early NSCLC US patients
Presenter: Jay Lee
Session: ePoster Display
1159P - Individualized methylation-based dynamic analysis of cell-free DNA in postoperative monitoring of resected lung cancer
Presenter: Kezhong Chen
Session: ePoster Display
1160P - Efficacy and biomarker identification of neoadjuvant chemo-immunotherapy in potentially resectable non-small cell lung cancer
Presenter: Yongchang Zhang
Session: ePoster Display
1161P - Can 18F-FDG-PET/CT predict PD-L1 expression in resected non-small cell lung cancer (NSCLC)?
Presenter: Daniel Hughes
Session: ePoster Display